Nathan D Trinklein
Overview
Explore the profile of Nathan D Trinklein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
4614
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Avanzino B, Prabhakar K, Dalvi P, Hartstein S, Kehm H, Balasubramani A, et al.
Oncoimmunology
. 2022 Aug;
11(1):2113697.
PMID: 36016696
The use of T-cell engagers (TCEs) to treat solid tumors is challenging, and several have been limited by narrow therapeutic windows due to substantial on-target, off-tumor toxicities due to the...
2.
Dang K, Castello G, Clarke S, Li Y, Balasubramani A, Boudreau A, et al.
J Immunother Cancer
. 2021 Jun;
9(6).
PMID: 34088740
Background: Therapeutic options currently available for metastatic castration-resistant prostate cancer (mCRPC) do not extend median overall survival >6 months. Therefore, the development of novel and effective therapies for mCRPC represents...
3.
Harris K, Lorentsen K, Malik-Chaudhry H, Loughlin K, Basappa H, Hartstein S, et al.
Sci Rep
. 2021 May;
11(1):10592.
PMID: 34011961
The use of recombinant interleukin-2 (IL-2) as a therapeutic protein has been limited by significant toxicities despite its demonstrated ability to induce durable tumor-regression in cancer patients. The adverse events...
4.
Malik-Chaudhry H, Prabhakar K, Ugamraj H, Boudreau A, Buelow B, Dang K, et al.
MAbs
. 2021 Apr;
13(1):1890411.
PMID: 33818299
The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents. Encouraging clinical data have been...
5.
Vafa O, Trinklein N
Front Oncol
. 2020 May;
10:446.
PMID: 32351885
This perspective highlights the history and challenges of developing CD3-based bispecific T-cell engagers (TCEs) as cancer therapeutics as well as considerations and potential strategies for designing the next generation TCE...
6.
Lam N, Trinklein N, Buelow B, Patterson G, Ojha N, Kochenderfer J
Nat Commun
. 2020 Mar;
11(1):1319.
PMID: 32152289
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
7.
Lam N, Trinklein N, Buelow B, Patterson G, Ojha N, Kochenderfer J
Nat Commun
. 2020 Jan;
11(1):283.
PMID: 31941907
Chimeric antigen receptor (CAR)-expressing T cells targeting B-cell maturation antigen (BCMA) have activity against multiple myeloma, but improvements in anti-BCMA CARs are needed. We demonstrated recipient anti-CAR T-cell responses against...
8.
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Trinklein N, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, et al.
MAbs
. 2019 Jan;
11(4):639-652.
PMID: 30698484
T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing activity in humans, but cytokine release-related toxicities have affected their clinical utility. The use of novel anti-CD3 binding domains with more...
9.
Clarke S, Ma B, Trinklein N, Schellenberger U, Osborn M, Ouisse L, et al.
Front Immunol
. 2019 Jan;
9:3037.
PMID: 30666250
Heavy chain-only antibodies (HCAbs) do not associate with light chains and their V regions are functional as single domains, forming the smallest active antibody fragment. These V regions are ideal...
10.
Harris K, Force Aldred S, Davison L, Ogana H, Boudreau A, Bruggemann M, et al.
Front Immunol
. 2018 May;
9:889.
PMID: 29740455
We created a novel transgenic rat that expresses human antibodies comprising a diverse repertoire of heavy chains with a single common rearranged kappa light chain (IgKV3-15-JK1). This fixed light chain...